Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to moderate COVID-19 in a European health system

Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/39360

View/Open:

Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to.pdf

1,01 MB
Adobe PDF
Share:

This resource is restricted

Title:
Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to moderate COVID-19 in a European health system

Editor:
Elsevier

Issue Date:
2023-12

Knowledge area:
CDU: Ciencias aplicadas: Medicina

Type of document:
info:eu-repo/semantics/article

Access rights:
info:eu-repo/semantics/closedAccess

DOI:
10.1016/j.ejim.2023.09.025

Published in:
European Journal of Internal Medicine, Vol. 118 (2023) p.133-135

Show full item record View statistics